Jan 7 (Reuters) - Immuneering Corp IMRX.O:
IMMUNEERING ANNOUNCES POSITIVE DATA UPDATE FROM THREE PANCREATIC CANCER ARMS OF ONGOING PHASE 2A TRIAL OF IMM-1-104; PLANS TO EXPAND TRIAL WITH ADDITIONAL ARMS
IMMUNEERING CORP - IMM-1-104 SHOWS 43% ORR AND 86% DCR IN PANCREATIC CANCER
IMMUNEERING CORP - IMM-1-104 WITH FOLFIRINOX SHOWS 100% LESION REDUCTION IN PANCREATIC CANCER
IMMUNEERING CORP - FURTHER IMM-1-104 PHASE 2A DATA EXPECTED IN 2Q’25
Source text: ID:nGNX3YBJtN
Further company coverage: IMRX.O
((Reuters.Brief@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.